Irritable bowel syndrome: New agents targeting serotonin receptor subtypes

Drugs

Volumn 61, Issue 3, 2001, Pages 317-332

  De Ponti, F ^a   Tonini, M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 4,5,6,7 TETRAHYDRO 5 (1 INDOLYLCARBONYL)BENZIMIDAZOLE; ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIARRHEAL AGENT; AZASETRON; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CILANSETRON; CISAPRIDE; DOLASETRON MESILATE; FABESETRON; GRANISETRON; KAPPA OPIATE RECEPTOR AGONIST; LOPERAMIDE; MOSAPRIDE CITRATE; MUSCARINIC M3 RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; ONDANSETRON; PIBOSEROD; PRUCALOPRIDE; SEROTONIN 1B AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN RECEPTOR; SOMATOSTATIN DERIVATIVE; SUMATRIPTAN; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DRUG INDUCED DISEASE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HUMAN; IRRITABLE COLON; PATHOPHYSIOLOGY; REVIEW;

EID: 0035057423     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161030-00001     Document Type: Review

References (138)

1. Irritable bowel syndrome: A technical review for practice guideline development
2. American Gastroenterological Association medical position statement: Irritable bowel syndrome
3. The functional gastrointestinal disorders and the Rome II process
4. Functional bowel disorders and functional abdominal pain
5. Intestinal gas dynamics and tolerance in humans
6. Recent advances in the pharmacology of gastrointestinal prokinetics
7. Controlled treatment trials in the irritable bowel syndrome: A critique
8. Basic and clinical aspects of visceral hyperalgesia
9. Functional gut disorders: From motility to sensitivity disorders: A review of current and investigational drugs for their management
10. Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery
11. Motility-modifying agents and management of disorders of gastrointetsinal motility
12. Pathobiology of visceral pain: Molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: A source of new therapeutic targets for abdominal pain
13. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans
14. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract
15. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
16. The role of psychological and biological factors in postinfective gut dysfunction
17. Psychometric scores and persistence of irritable bowel after infectious diarrhoea
18. Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations
19. The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disorders
20. Irritable bowel syndrome: New pharmaceutical approaches to treatment
21. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia
22. Imipramine decreases oesophageal pain perception in human male volunteers
23. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans
24. Review article: Clinical pharmacology models of irritable bowel syndrome
25. Ten secrets for development of drugs for functional gastrointestinal diseases
26. Design of treatment trials for functional gastrointestinal disorders
27. Assessment of treatment outcome in the functional gastrointestinal disorders
28. Review article: The safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients
29. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
30. The importance of 5-hydroxytryptamine receptors in the gut
31. Gastrointestinal prokinetic benzamides: The pharmacology underlying stimulation of motility
32. Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle
33. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons
34. Serotonin modulation of gastrointestinal motility
35. Differential localization of 5-HT1 receptors on myenteric and submucosal neurons
36. 5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: Potential mechanisms
37. Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells
38. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus
39. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans
40. 5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine
41. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man
42. Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT
43. - efflux from rat colonocytes
44. Review article: The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome
45. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl) carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue
46. 5-HT3 receptor involvement in descending reflex relaxation in the rabbit isolated distal colon
47. 3 receptor in stress-induced defecation
48. 4 receptor dual antagonist, on colonic function in vivo
49. Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum
50. Differential distribution of 5-hydroxytryptamine3 receptor in the colon between human and guinea pig
51. 3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum
52. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (5HT) via 5-HT4 and 5-HT3 receptors
53. 3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides
54. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study
55. 3 receptor antagonist, slows colonic transit in healthy man
56. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist
57. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans
58. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia?
59. 3-receptor antagonist, in patients with irritable bowel syndrome
60. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea
61. 5-Hydroxytryptamine and functional bowel disorders
62. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension
63. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist
64. 3 receptor antagonists in modulation of visceral hypersensitivity
65. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)
66. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility
67. Alosetron slows colonic transit in patients with irritable bowel syndrome (IBS)
68. Alosetron, a 5-HT3 receptor antagonist, has no effect on oro-cecal transit time in man
69. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
70. 4 receptors on the human stomach
71. Ability of mosapride to bind to 5-HT4 receptor in the human stomach
72. Evidence against an acetylcholine releasing action of cisapride in the human colon
73. Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut
74. Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens
75. The guinea-pig distal colon-a sensitive preparation for the investigation of 5-HT4 receptor-mediated contractions
76. Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle
77. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors
78. 4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle
79. 1p receptors on sensory CGRP neurons
80. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea-pig intestine
81. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
82. Review article: Clinical pharmacology of alosetron
83. Alosetron
84. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat
85. Alosetron does not affect the visceral perception of gastric distension in healthy subjects
86. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome
87. 3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat
88. 4 agonist, prucalopride, in healthy humans
89. Tegaserod
90. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)
91. Single-dose and once-daily pharmacokinetics and effects of food on prucalopride in humans
92. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist
93. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration
94. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
95. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
96. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
97. Cisapride increases micturition frequency
98. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle
99. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres
100. Review article: Cardiac adverse effects of gastrointestinal prokinetics
101. The long QT syndromes: Genetic basis and clinical implications
102. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
103. QT interval prolongation by non-cardiac drugs: Lessons to be learned by recent experience
104. Drug interactions with cisapride: Clinical implications
105. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
106. Intestinal prokinesia by two esters of 4-amino-5-chloro-2- methoxybenzoic acid: Involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo
107. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart
108. Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS)
109. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
110. Prucalopride (PRU) improves colonic transit and stool frequency in patients (pts) with slow and normal transit constipation
111. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS)
112. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals
113. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro
114. Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome
115. Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod
116. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
117. 4 receptor partial agonist, on colorectal distension in rats
118. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers
119. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
120. A double-blind, placebo controlled evaluation of safety and efficacy of 12-week, twice-daily treatment with prucaloprid in patients with chronic constipation
121. Mosapride price-listed in Japan
122. The effect of mosapride, anovel prokinetic, on acid reflux variables in patients with gastro-oesohageal reflux disease
123. SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models
124. 4 receptor antagonist SB-207266 on gastrointetsinal motor and sensory function in humans
125. Increased defecation during stress or after 5-hydroxytryptophan: Selective inhibition by the 5-HT4 receptor antagonist, SB-207266
126. A pharmacodynamic model of 5-HT4 receptor activation in man: Antagonism by the 5-HT4 receptor antagonist SB-207266
127. 5-HT4 receptor antagonism in irritable bowel syndrome: Effect of SB-207266-A on rectal sensitivity and small bowel transit
128. 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats
129. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man
130. Role of impaired gastric accommodation to a meal in functional dyspepsia
131. Influence of sumatriptan-induced colonic relaxation on the perception of colonic distention in man
132. Influence of buspirone-induced fundus relaxation on the perception of gastric distention in man
133. 1B/D receptor antagonist GR127935 of the effect of sumatriptan on canine gastric compliance
134. 1A-receptors
135. 7 receptors: Current knowledge and future prospects
136. New and future drugs in nerve-gut dysfunction
137. 2 receptors in normal and altered rectal sensitivity in rats
138. Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon